EUVIMEDEUVIMED entdecken
Crossref

Harnessing the E3 Ligase KLHL12 for Tumor‐Selective Protein Degradation

Shicheng Xu, Xian Zhang, Shunbo Hu, Xinyi Wang, Yuxin Ge, Ziquan Zhao, Tianbao Zhu, Nan Wang, Limin Du, Qidong You, Xiaoke Guo, Zhengyu Jiang iD

Angewandte Chemie International Edition · 2026

DOI: 10.1002/anie.3312795 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Angewandte Chemie International Edition, 2026. Verfasst von Shicheng Xu und 11 weiteren Autor:innen. Beteiligte Einrichtung: Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanji…. Hauptthemen laut MEDLINE: Ubiquitin-Protein Ligases, Antineoplastic Agents. Die Arbeit nennt 55 Literaturangaben. Gefördert von: National Natural Science Foundation of China, National Key Research and Development Program of China, Basic Research Program of Jiangsu.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Proteolysis‐targeting chimeras (PROTACs) are currently constrained by a reliance on ubiquitously expressed E3 ligases, which compromises tumor selectivity and raises toxicity risks. Here, we identified KLHL12 as a potentially tumor‐selective E3 ligase and reported the development of the first‐in‐class KLHL12‐recruiting PROTACs. Guided by a structure‐based macrocyclization strategy, we obtained a high‑affinity cyclic peptide, cp4 , as a KLHL12‑binding ligand and constructed novel PROTACs against oncogenic BRD4 and EGFR. The optimal compound k12bp‐1 achieved tumor‐selective BRD4(L) degradation in A549 cells, significantly inhibiting cell proliferation and driving cell apoptosis while sparing normal cells. It demonstrated robust in vivo antitumor efficacy in A549 xenograft mouse models without observable systemic toxicity. Collectively, this work established KLHL12 as a promising tumor‑selective E3 ligase and provided a KLHL12‐recruiting PROTAC platform for cancer therapy.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Ubiquitin-Protein LigasesAntineoplastic AgentsHumansAnimalsProteolysisMiceProteolysis Targeting ChimeraCell ProliferationCell Line, TumorBromodomain Containing ProteinsTranscription FactorsCell Cycle ProteinsApoptosis

Stichwörter der Autor:innen

KLHL12protein degradationproteolysis‐targeting chimerastumor‐selective

Substanzen

Ubiquitin-Protein LigasesProteolysis Targeting ChimeraAntineoplastic AgentsBromodomain Containing ProteinsTranscription FactorsCell Cycle ProteinsBRD4 protein, human

Autor:innen und Institutionen

  • Jiangsu Key Laboratory of Drug Design and Optimization, Department of Medicinal Chemistry, School of Pharmacy, China Pharmaceutical University, Nanjing, China.

ORCID-Profile: Zhengyu Jiang

Förderung

  • National Natural Science Foundation of China
  • National Key Research and Development Program of China
  • Basic Research Program of Jiangsu
  • Jiangsu Funding Program for Excellent Postdoctoral Talent

Zitieren

APA

Xu, S., Zhang, X., Hu, S., Wang, X., Ge, Y., Zhao, Z., Zhu, T., Wang, N., Du, L., You, Q., Guo, X., & Jiang, Z. (2026). Harnessing the E3 Ligase KLHL12 for Tumor‐Selective Protein Degradation. Angewandte Chemie International Edition. https://doi.org/10.1002/anie.3312795

Vancouver

Xu S, Zhang X, Hu S, Wang X, Ge Y, Zhao Z, et al. Harnessing the E3 Ligase KLHL12 for Tumor‐Selective Protein Degradation. Angewandte Chemie International Edition. 2026. doi:10.1002/anie.3312795

BibTeX
@article{Xu2026,
  author = {Xu, Shicheng and Zhang, Xian and Hu, Shunbo and Wang, Xinyi and Ge, Yuxin and Zhao, Ziquan and Zhu, Tianbao and Wang, Nan and Du, Limin and You, Qidong and Guo, Xiaoke and Jiang, Zhengyu},
  title = {Harnessing the E3 Ligase KLHL12 for Tumor‐Selective Protein Degradation},
  journal = {Angewandte Chemie International Edition},
  year = {2026},
  doi = {10.1002/anie.3312795}
}
Kostenlos starten →